Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has announced the FDA’s acceptance of their Fast Track Designation submission for intranasal foralumab, a potential treatment for secondary-progressive multiple sclerosis. The treatment has shown promise in early access programs with a majority of patients experiencing reduced fatigue and stabilized disease progression. Fast Track Designation could expedite foralumab’s review and development, addressing the unmet need for therapies in this area.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
